-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49

Benzinga·08/17/2026 14:28:25
Listen to the news
UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $45 to $49.